Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A nonparametric method to detect increased frequencies of adverse drug reactions over time.

Heimann G, Belleli R, Kerman J, Fisch R, Kahn J, Behr S, Berlin C.

Stat Med. 2018 Apr 30;37(9):1491-1514. doi: 10.1002/sim.7593. Epub 2018 Jan 10.

PMID:
29322542
2.

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA.

Do TP, Seetasith A, Belleli R, Schlienger RG, Corda S, Burudpakdee C, Streefkerk HJ, Behr S.

Am J Cardiovasc Drugs. 2018 Jun;18(3):205-211. doi: 10.1007/s40256-017-0256-x.

PMID:
29177815
3.

Assessing switchability for biosimilar products: modelling approaches applied to children's growth.

Belleli R, Fisch R, Renard D, Woehling H, Gsteiger S.

Pharm Stat. 2015 Jul-Aug;14(4):341-9. doi: 10.1002/pst.1691. Epub 2015 May 19.

PMID:
25989222
4.

Regulatory watch: Efficiency indicators for new drugs approved by the FDA from 2003 to 2013.

Belleli R, Fisch R, Szucs TD.

Nat Rev Drug Discov. 2015 Mar;14(3):156. doi: 10.1038/nrd4563. No abstract available.

PMID:
25722232
5.

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.

John MR, Harfst E, Loeffler J, Belleli R, Mason J, Bruin GJ, Seuwen K, Klickstein LB, Mindeholm L, Widler L, Kneissel M.

Bone. 2014 Jul;64:204-10. doi: 10.1016/j.bone.2014.04.015. Epub 2014 Apr 24.

PMID:
24769332
6.

ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.

John MR, Widler L, Gamse R, Buhl T, Seuwen K, Breitenstein W, Bruin GJ, Belleli R, Klickstein LB, Kneissel M.

Bone. 2011 Aug;49(2):233-41. doi: 10.1016/j.bone.2011.04.007. Epub 2011 Apr 14.

PMID:
21514409
7.

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.

Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR.

Bone. 2009 Dec;45(6):1053-8. doi: 10.1016/j.bone.2009.07.091. Epub 2009 Aug 11.

PMID:
19679211
8.

Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.

Sechaud R, Robeva A, Belleli R, Balez S.

Int J Clin Pharmacol Ther. 2008 Oct;46(10):519-26.

PMID:
18826866
9.

Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.

Séchaud R, Robeva A, Belleli R, Balez S.

J Clin Pharmacol. 2008 Aug;48(8):919-25. doi: 10.1177/0091270008320316. Epub 2008 May 28.

PMID:
18508948
10.

Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.

Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Rivière GJ, Balez S, Alberti D, Séchaud R.

J Clin Pharmacol. 2008 Apr;48(4):428-35. doi: 10.1177/0091270007313327. Epub 2008 Feb 15.

PMID:
18281442
11.

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D.

Haematologica. 2006 Oct;91(10):1343-51.

Supplemental Content

Loading ...
Support Center